Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00102531 · ClinicalTrials.gov registry record · Phase 1
Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
A Phase 1 study of Osteosarcoma Metastatic, sponsored by Insmed Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 2
- Study locations
NCT00102531: Completed Phase 1 study of Osteosarcoma Metastatic, sponsored by Insmed Incorporated.
NCT00102531 is a Phase 1 study of Osteosarcoma Metastatic that has completed, run by Insmed Incorporated. The registered enrollment target is 19 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00102531, a Phase 1 study of Osteosarcoma Metastatic, has completed, sponsored by Insmed Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 2
- Study locations
Study Summary
Phase Ib/IIa open label safety and efficacy study designed to determine the maximum tolerated dose of inhaled cisplatin liposomal (SLIT cisplatin) administered every 14 days to patients with relapsed/progressive osteosarcoma metastatic to the lung.
Conditions Studied
Interventions
- DRUG Cisplatin liposomal
Study Locations (2)
New York
- Memorial Sloan Kettering Cancer Center - New York
- The Albert Einstein College of Medicine Montefiore Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2005-01-12 |
| Est. Completion | 2008-03-17 |
| Phase | Phase 1 |
What the finished NCT00102531 record still lists
NCT00102531 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (68% lower).
The record links to 1 condition, with Osteosarcoma Metastatic appearing as the primary indexed condition, and to 1 intervention - of which Cisplatin liposomal is the first listed.
NCT00102531 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00102531 about?
NCT00102531 is a clinical study titled "Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung". Phase Ib/IIa open label safety and efficacy study designed to determine the maximum tolerated dose of inhaled cisplatin liposomal (SLIT cisplatin) administered every 14 days to patients with relapsed/progressive osteosarcoma metastatic to the lung.
What is the current status of trial NCT00102531?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2005-01-12. Estimated completion is 2008-03-17.
What conditions does trial NCT00102531 study?
This clinical trial studies the following conditions: Osteosarcoma Metastatic.
What interventions are being tested in trial NCT00102531?
The interventions under investigation include: Cisplatin liposomal (DRUG).
Who is sponsoring clinical trial NCT00102531?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00102531 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteosarcoma Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00102531's enrollment target sits among peer trials
19 1716th of 2000 higher than 281 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI